文献速递泌尿男性生殖肿瘤

每周卡巴他赛联合泼尼松治疗不适合标准方案的转移性去势抵抗性前列腺癌:II期SOGUG试验

Weekly cabazitaxel plus prednisone is effective and less toxic for 'unfit' metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial.
PubMed 文献 · Eur J Cancer · 2017-11-02

这项单臂II期研究评估每周卡巴他赛(10 mg/m²,第1、8、15、22天给药,每5周重复)联合泼尼松(5 mg每日两次)用于多西他赛失败后不适合标准方案的转移性去势抵抗性前列腺癌患者。≥50%和≥80%的PSA缓解率分别为34.8%和10.6%,中位PSA-PFS为4.8个月,3/4级毒性发生率低。

要点

  • 每周卡巴他赛方案在多西他赛失败后的不适合患者中显示与标准3周方案相当的疗效。
  • 3/4级血液学毒性低(中性粒细胞减少2.8%、白细胞减少5.7%、血小板减少9%),无发热性中性粒细胞减少。
  • 早期循环肿瘤细胞应答与PSA-PFS显著相关,或可作为早期疗效终点。

核心结论

  • 每周卡巴他赛联合泼尼松在不适合标准方案的mCRPC患者中疗效与经典3周方案(TROPIC研究)相当,且毒性显著更低、耐受性更好。
  • 早期CTC应答可能作为治疗疗效的早期终点指标。

研究设计与样本

  • 卡巴他赛10 mg/m²每周一次1小时输注,第1、8、15、22天给药,每5周重复;口服泼尼松5 mg每日两次。
  • 主要有效性标准为至少65%的患者在第12周达到基于PSA-PFS的临床获益标准。

主要发现

  • 总体71.4%的患者ECOG-PS为2;骨、肝、肺转移分别占84%、16%、11%。
  • 客观部分缓解或疾病稳定率为61%;PSA缓解≥50%和≥80%分别为34.8%和10.6%。
  • 中位PSA-PFS为4.8个月;68.6%的患者在第12周无进展。
  • 最常见的3/4级毒性为中性粒细胞减少(2.8%)、白细胞减少(5.7%)和血小板减少(9%);无发热性中性粒细胞减少病例。
  • 早期CTC应答与PSA-PFS显著相关。

关键数值与推荐

  • 有效性判定标准:至少65%的患者在第12周达到基于PSA-PFS的临床获益。
  • 实际第12周无进展比例为68.6%,达到预设有效性阈值。
  • PSA缓解≥50%和≥80%分别为34.8%和10.6%;中位PSA-PFS为4.8个月。
  • 3/4级中性粒细胞减少2.8%、白细胞减少5.7%、血小板减少9%;无发热性中性粒细胞减少。

临床怎么用

  • 对于多西他赛失败后不适合标准3周方案的mCRPC患者,可考虑每周卡巴他赛联合泼尼松方案。
  • 治疗期间应监测血常规,但严重血液学毒性发生率较低。
  • 早期CTC应答可能有助于早期评估疗效,但需进一步验证。

局限性

  • 有效性判断基于与历史研究(TROPIC)的间接比较。
  • 早期CTC应答作为疗效终点的价值需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Cabazitaxel (CBZ), a novel tubulin-binding taxane, improves overall survival in metastatic castration-resistant prostate cancer (mCRPC) that progresses during or after docetaxel treatment. We have designed a phase II study to evaluate the efficacy and safety of CBZ as a weekly schedule for 'unfit' mCRPC patients after docetaxel failure. METHODS: In this single arm phase II study. CBZ was weekly administered in 1-hour infusion on days 1, 8, 15 and 22, every 5 weeks at 10 mg/m2 to eligible 'unfit' patients; oral prednisone (5 mg) was administered twice a day. Circulating tumour cells (CTCs) were also collected. New treatment scheme was considered effective if at least 65% of patients met a clinical benefit criteria based on prostate-specific antigen (PSA)-progression-free survival (PFS) values at week 12. RESULTS: Seventy patients (median age: 73.9 years) were enrolled; overall, 71.4% had an Eastern Cooperative Oncology Group Performance Status (ECOG-PS) of 2; and 84%, 16% and 11% had bone, liver and lung metastases, respectively. Objective partial response or stable disease was achieved in 61% of patients, while PSA responses of ≥50% and ≥80% were observed in 34.8% and 10.6%, respectively. The median PSA-PFS was 4.8 months; and 68.6% of patients had no progression at week 12. The most frequent grade 3/4 toxicities were neutropenia (2.8%), leukopenia (5.7%) and thrombocytopaenia (9%); no cases of febrile neutropenia were reported. Early CTC response was significantly correlated with PSA-PFS. CONCLUSIONS: CBZ/prednisone administered weekly to 'unfit' mCRPC patients appears to be as effective as classical standard 3-week scheme (TROPIC study) but with significantly lower toxicities and better tolerance. Early CTC response appears to be valuable as an early end-point of therapeutic efficacy.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Climent MÁ, Pérez-Valderrama B, Mellado B, et al. Weekly cabazitaxel plus prednisone is effective and less toxic for 'unfit' metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial. Eur J Cancer. 2017. PMID: 29102858. doi:10.1016/j.ejca.2017.09.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。